News | February 05, 2010

Drug Trial Started to Prevent, Treat Venous Thromboembolism

February 5, 2010 – A new, large-scale pivotal phase III trial has been initiated for edoxaban to evaluate its safety and efficacy in reducing recurrent venous thromboembolic (VTE) complications in patients with deep-vein thrombosis (DVT) and/or pulmonary embolism (PE).

The primary efficacy endpoint for the HOKUSAI VTE trial is the recurrence of symptomatic VTE (i.e., the composite of DVT, nonfatal PE and fatal PE). The primary safety assessment of the trial is the incidence of major and clinically relevant non-major bleeding. Edoxaban is an investigational oral Factor Xa inhibitor

"The incidence of VTE is predicted to double by 2050," said Harry R. Büller, M.D., professor of internal medicine, chairman of the department for vascular medicine at the Academic Medical Center, Amsterdam and chairman of the steering committee for HOKUSAI VTE. "Based on what we've seen in phase II and other trials, edoxaban shows promise as an agent to help fulfill the need for treatment options that are safe, effective and more convenient than the current standard of care, which requires extensive monitoring, careful dose adjusting and may have the potential for various drug and food interactions."

HOKUSAI VTE is the largest, single phase III study ever undertaken in the area of VTE. The multicenter study that will include approximately 7,500 patients in more than 450 clinical sites in approximately 40 countries worldwide. This is an event-driven, randomized, double-blind, double-dummy, parallel-group, multicenter, multinational study, which will randomize patients to two different treatment groups. Both groups will receive open label enoxaparin or unfractionated heparin for at least five days and up to 12 days, followed by double-blind warfarin or edoxaban 60 mg once-daily. Patients will be treated for up to 12 months in accordance to the standard of care and international guidelines.

For more information: www.daiichisankyo.com

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init